Anil P. Ranganath Sells 686 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) insider Anil P. Ranganath sold 686 shares of the stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider now directly owns 13,955 shares of the company's stock, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

TransMedics Group Stock Up 1.4%

NASDAQ:TMDX traded up $2.02 during midday trading on Wednesday, reaching $142.88. The company had a trading volume of 978,136 shares, compared to its average volume of 1,361,209. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The firm has a market capitalization of $4.83 billion, a price-to-earnings ratio of 152.00 and a beta of 2.10. The stock's fifty day simple moving average is $104.27 and its 200-day simple moving average is $81.15.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.41. The business had revenue of $143.54 million during the quarter, compared to analysts' expectations of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company's revenue for the quarter was up 48.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.35 EPS. On average, sell-side analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Institutional Trading of TransMedics Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TMDX. NBC Securities Inc. purchased a new position in shares of TransMedics Group in the 1st quarter valued at $25,000. Smartleaf Asset Management LLC boosted its stake in TransMedics Group by 44.3% in the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after acquiring an additional 135 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new position in shares of TransMedics Group during the fourth quarter worth about $31,000. Quarry LP increased its position in shares of TransMedics Group by 88.5% during the first quarter. Quarry LP now owns 592 shares of the company's stock worth $40,000 after purchasing an additional 278 shares in the last quarter. Finally, Hager Investment Management Services LLC increased its position in shares of TransMedics Group by 38.3% during the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock worth $50,000 after purchasing an additional 205 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on TMDX shares. Oppenheimer increased their price objective on shares of TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research report on Tuesday, June 3rd. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, Piper Sandler reissued an "overweight" rating and set a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $125.11.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.